Tuesday, March 13, 2012 8:55:41 PM
So you sold and now you can't find the article? But it was well written, something like this below? Showing that Atrinsic was ahead on its payments? Also I'd like to see one piece of proof that ATRN is in default today, because if that was the case, we would of had see a 8k on a share offering like every other company does that is in trouble. I don't see any current 8k addressing a share increase, or default, DO YOU?.
Item 8.01 Other Events
On May 31, 2011, the Company sold to investors Secured Convertible Promissory Notes (the "Notes") in the original aggregate principal amount of $5,813,500. As of the close of business on January 26, 2012, an aggregate principal amount of approximately $4,100,000 remained outstanding on the Notes. The Company intends to use the net cash proceeds of $615,000 received from its January 23, 2012 sale of certain short codes, domain names, trademarks and databases used in the Company's subscription businesses to Mkono Media Corp. to further reduce its obligations under the Notes.
http://biz.yahoo.com/e/120127/atrn.pk8-k.html
Item 8.01 Other Events
On May 31, 2011, the Company sold to investors Secured Convertible Promissory Notes (the "Notes") in the original aggregate principal amount of $5,813,500. As of the close of business on January 26, 2012, an aggregate principal amount of approximately $4,100,000 remained outstanding on the Notes. The Company intends to use the net cash proceeds of $615,000 received from its January 23, 2012 sale of certain short codes, domain names, trademarks and databases used in the Company's subscription businesses to Mkono Media Corp. to further reduce its obligations under the Notes.
http://biz.yahoo.com/e/120127/atrn.pk8-k.html
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
